Orthobiologics are substances, found in human body, used for faster healing process of injuries such as, broken bones, injured muscles, and ligaments. These substances are made up of substances found in human body. When orthobiologics are used in higher concentration, they help in accelerating healing process. The faster recovery process, reduction in number hospital visits, and accelerated healing are the benefits due to which orthobiologics are gaining prominence.
The key factors driving the growth of the global orthobiologics market are increase in road accidents & sports injuries, rise in obesity rate, awareness among patients & athletes, and rapidly aging population. However, high cost of procedures, stringent regulatory approval procedures for each of the orthobiologic products, and lack of reliable clinical trial data are factors restraining the growth of this market. Advancements in implant technologies and growing demand of biological solutions as compared to mechanical solution create opportunities for its growth.
The global orthobiologics market is segmented based on product, end user, and geography. The market is further classified based on product into bone allograft, stem cell therapy, bone graft substitutes, bone growth factors & spinal stimulation, and viscosupplementation. On the basis of end user, the market is further categorized into hospitals, orthopedic clinics, and others. The market segmented geographically into North America, Europe, Asia, and Rest of the World (RoW).
The key manufacturers profiled in the report are Biomet Inc., Stryker Corporation, Medtronic PLC., Integra Life Sciences Corporation, Zimmer Inc., DePuy Synthes, Exactech Inc., Tornier Inc., Globus Medical Inc., Nuvasive Inc., and Wright Medical Technology Inc. The manufacturers implement strategies, such as agreements, partnerships, mergers & acquisitions, and others to gain the prominence in the market.
KEY BENEFITS FOR STAKEHOLDERS:
KEY MARKET SEGMENTS: